Education
About Us
Working with TipRanks
Follow Us
Psyence Group (TSE:PSYG)
:PSYG
PSYG Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.11 - C$0.53
Previous CloseN/A
Volume20.00K
Average Volume (3M)1.64K
Market Cap
C$2.58M
Enterprise ValueC$26.22M
Total Cash (Recent Filing)C$1.11M
Total Debt (Recent Filing)C$12.41M
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Sep 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,638,267
10 Day Avg. Volume750
30 Day Avg. Volume1,639
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Psyence Group News
PSYG FAQ
What was Psyence Group’s price range in the past 12 months?
Psyence Group lowest stock price was C$0.10 and its highest was C$0.53 in the past 12 months.
What is Psyence Group’s market cap?
Psyence Group’s market cap is C$2.58M.
When is Psyence Group’s upcoming earnings report date?
Psyence Group’s upcoming earnings report date is Sep 01, 2025 which is in 4 days.
How were Psyence Group’s earnings last quarter?
Currently, no data Available
Is Psyence Group overvalued?
According to Wall Street analysts Psyence Group’s price is currently Overvalued.
Does Psyence Group pay dividends?
Psyence Group does not currently pay dividends.
What is Psyence Group’s EPS estimate?
Psyence Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Psyence Group have?
Psyence Group has 15,638,267 shares outstanding.
What happened to Psyence Group’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Psyence Group?
Currently, no hedge funds are holding shares in TSE:PSYG
Company Description
Psyence Group
Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
Technical Analysis
Braxia Scientific
―
New Leaf Ventures
―
Entheon Biomedical
―
Silo Wellness Inc
―
Revitalist Lifestyle & Wellness Ltd
―
Ownership Overview
0.82% Insiders
―
Mutual Funds
― Other Institutional Investors
99.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---